2015年3月21日讯/生物谷BIOON/--近日，阿特维斯（Actavis）以705亿美元的总价完成对艾尔建（Allergan）的收购。
两家公司的合并将会在销售额上跻身全球前十大制药公司，预计今年的总收益将会超过230亿美元。
阿特维斯的CEO和董事长Brent Saunders表示，合并后的公司将以客户为中心，致力于加强与医生、药剂师和病人的合作，开发创新治疗方式，加强新药推广。如今收购已经完成，阿特维斯将立即开始实施全面的整个计划，确保全球合作，为可持续的健康增长扩大基础。
此次收购大幅增长了阿特维斯的全球商业机会，商业布局已经扩展到全球100个国家。2015年，合并后的阿特维斯将会在研发上投入170亿美元。阿特维斯还将收购Allergan的明星产品Botox，主要成分是高纯度的肉毒素，用于除皱和瘦脸。这款产品在过去的五年中除了用于化妆品行业，还获批用于很多医疗用途，预计在将来会是阿特维斯的主要增长型产品。
阿特维斯甚至还计划将公司名改为Allergan。去年阿特维斯与加拿大制药公司Valeant展开了激烈的Allergan投标争夺，Valeant报价530亿美元，但最终还是不敌白衣骑士阿特维斯，最近有传闻Valeant已经通过提价约10亿美元，在竞购战中击败对手Endo国际公司，将以约111亿美元的全现金出价购买Salix药业。
原文 Actavis completes $70.5bn Allergan acquisition
Actavis has completed its acquisition of Allergan for a total value of around $70.5bn.
The combination of the two companies will create one of the world's top ten pharma companies by sales revenue， with combined annual pro forma revenue of more than $23bn anticipated for this year.
Brent Saunders， CEO and president of Actavis， said： “Our combined company will be built around a customer-focused commitment to partnering with physicians， pharmacists and patients to deliver innovative treatments and enhance access to important therapies around the world.
“With the acquisition now complete， we will immediately begin implementing our comprehensive integration plans to ensure that we leverage our strengthened global organisation to generate sustainable organic earnings growth from our newly expanded base.”
The combination enhances Actavis' international commercial opportunities， with its commercial presence spanning across around 100 countries around the world.
The combined company is expected to invest $1.7bn into its R&D programmes for 2015.
Actavis will also be buying into Allergan's lead product Botox， which has over the past five years gained more medical-based licences outside of its cosmetic indications， and is seen as a major growth product for the future.
Actavis has also said it plans to change its name to Allergan.
The finalisation comes after a bidding war with Canadian pharma firm Valeant， who lodged a bid of around $53bn for Allergan at the end of last year.
But Valeant may not be too disappointed as just this week， the firm raised its offer for specialty drugmaker Salix - after its previous bid was trumped by Ireland-based Endo - and has seemingly sealed the deal with a final $11bn offer.